# AstraZeneca’s Enhertu approved in the US for gastric cancer

- Link: https://www.directorstalkinterviews.com/astrazenecas-enhertu-approved-in-the-us-for-gastric-cancer/412954032
- Published: 2021-01-18T07:33:46+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Daiichi Sankyo Company, Limited’s_ Enhertu_ (trastuzumab deruxtecan) has been
approved in the US for the treatment of adult patients with locally advanced or 
metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
who have received a prior trastuzumab-based regimen.

In the US, gastric cancer is most frequently diagnosed in the advanced stage, with
only approximately 5% of patients surviving beyond five years.^(1,2) Approximately
one in five gastric cancers are HER2 positive.^(3)

The approval by the Food and Drug Administration (FDA) was based on the positive
results from the randomised DESTINY-Gastric01 Phase II trial conducted in Japan 
and South Korea. In the trial, _Enhertu_ demonstrated a statistically significant
and clinically meaningful improvement in overall survival (OS) and objective response
rate (ORR) versus chemotherapy (irinotecan or paclitaxel) in patients with advanced
gastric cancer or GEJ adenocarcinoma who had progressed on at least two or more 
prior regimens including trastuzumab plus a fluoropyrimidine- and platinum-based
chemotherapy combination.^(4)

> **Ronan Kelly, MD, MBA, Director of the Charles A. Sammons Cancer Center and the
> W.W. Caruth, Jr. Chair of Immunology at Baylor University Medical Center, Dallas,
> Texas, US, said**: “Patients with metastatic HER2-positive gastric cancer with
> progression following 1st-line treatment have historically faced poor outcomes,
> including low response to treatment and rapid disease progression. This approval
> represents the first time a HER2-directed medicine has demonstrated a significant
> improvement in survival compared to chemotherapy following initial treatment in
> the metastatic setting, and it has the potential to become the new standard of
> care for this patient population.”

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit, said:** “
> Today’s approval of _Enhertu_ represents the first HER2-directed medicine approved
> in a decade for patients with HER2-positive metastatic gastric cancer. The results
> from the DESTINY-Gastric01 trial highlight the potential to change clinical practice,
> showing a 41 per cent improvement in survival and a response rate more than three
> times higher with _Enhertu_ compared to chemotherapy. We are thrilled to bring
> this important medicine to more patients and physicians in the US.”

> **Antoine Yver, Executive Vice President and Global Head, Oncology Research and
> Development, Daiichi Sankyo, said**: “_Enhertu_ is the first antibody drug conjugate
> to receive approval in the US for the treatment of patients with metastatic gastric
> cancer, and represents a major advance in managing this difficult-to-treat disease.
> This second indication in the US represents an important step forward in our ambitious
> plan to accelerate the development of _Enhertu_ across a broad range of HER2-targetable
> cancers.”

In a pre-specified interim analysis from the DESTINY-Gastric01 trial, patients treated
with _Enhertu_ had a 41% reduction in the risk of death versus patients treated 
with chemotherapy (based on a hazard ratio [HR] of 0.59; 95% confidence interval[
CI] 0.39-0.88; p=0.0097) with a median OS of 12.5 months versus 8.4 months.^(3)

Confirmed ORR, assessed by independent central review was a major efficacy outcome.
Results showed a confirmed ORR of 40.5% in patients treated with _Enhertu_ (n=126)
compared to 11.3% in patients treated with chemotherapy (n=62). Patients treated
with _Enhertu_ had a 7.9% complete response rate and a 32.5% partial response rate
compared to a complete response rate of 0% and a partial response rate of 11.3% 
for patients treated with chemotherapy.^(4)

_Enhertu _demonstrated a median progression-free survival (PFS) of 5.6 months compared
to 3.5 months with chemotherapy (HR=0.47; 95% CI 0.31-0.71). Additionally, _Enhertu_
showed a median duration of response (DoR) of 11.3 months versus 3.9 months with
chemotherapy.^(4)

Results from the DESTINY-Gastric01 trial were published in The New England Journal
of Medicine_ _in June 2020.^(5)

The most common adverse reactions, including laboratory abnormalities, of any grade(
greater than or equal to 20%) for patients treated with _Enhertu_ (n=125) in the
DESTINY-Gastric01 trial were anaemia, leukopenia, neutropenia, lymphocytopenia, 
thrombocytopenia, nausea, decreased appetite, increased aspartate aminotransferase,
fatigue, increased blood alkaline phosphatase, increased alanine aminotransferase,
diarrhoea, hypokalaemia, vomiting, constipation, increased blood bilirubin, pyrexia
and alopecia. Interstitial lung disease or pneumonitis occurred in 10% of patients.
^(4)

This is the second indication approved for _Enhertu_ in the US following the accelerated
approval for adult patients with unresectable or metastatic HER2-positive breast
cancer who have received two or more prior anti-HER2-based regimens in the metastatic
setting based on the DESTINY-Breast01 trial.

_Enhertu _was previously granted Priority Review, Breakthrough Therapy Designation(
BTD) in HER2-positive metastatic gastric cancer and Orphan Drug Designation for 
gastric cancer by the FDA. Two additional Phase II trials, DESTINY-Gastric02 and
DESTINY-Gastric03, are underway, further evaluating treatment with _Enhertu_ in 
patients with HER2-positive metastatic gastric cancer.

**Financial considerations**

Following US approval, an amount of $115m is due from AstraZeneca to Daiichi Sankyo
as a combined 2nd-line and 3rd-line milestone payment in HER2-positive gastric cancer.
In AstraZeneca, the milestones paid will be capitalised as an addition to the upfront
payment made in 2019 and subsequent capitalised milestones and amortised through
the profit and loss.

Sales of _Enhertu_ in the US are recognised by Daiichi Sankyo. AstraZeneca reports
its share of gross profit margin from _Enhertu_ sales in the US as collaboration
revenue in the Company’s financial statements. For further details on the financial
arrangements, please consult the collaboration agreement from March 2019.

Share on:
